I have not yet seen the full impact of pembrolizumab in the early setting on that population, but we’ve had, and we all do have, the population of patients who go through early therapy, our best therapy and have progression within 6 months. Those patients really don’t do well, so, ...
Merck’s anti-PD-1 therapy, met its overall survival (OS) endpoint, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant) for the treatment of patients ...
Prognostic factors were determined using univariate and multivariate stepwise log-rank analysis on disease-free survival (DFS) and overall survival (OS). Results This analysis included 128 women with early-stage TNBC. Clinical and histological characteristics are summarized below. After a median follow-...
Chemotherapy currently remains the standard treatment for triple-negative breast cancer (TNBC). However, TNBC frequently develop chemoresistance, which is responsible for cancer recurrence and distal metastasis. Both DNA damage repair and stemness are re
Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer.
HDAC9 activated the VEGF and MAPK3 kinase pathways by modulating the miR-206 expression and enhanced the cell invasion and angiogenesis in TNBCs33. The HDAC10 reduced the overall survival rate in TNBC patients by decreasing the expression of ESR134. On the same line, the high HDAC11 expressi...
Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese society of breast surgery 021). Chin Med J (Engl). 2022;135(6):697–706. Article CAS Pub...
HDAC9 activated the VEGF and MAPK3 kinase pathways by modulating the miR-206 expression and enhanced the cell invasion and angiogenesis in TNBCs33. The HDAC10 reduced the overall survival rate in TNBC patients by decreasing the expression of ESR134. On the same line, the high HDAC11 expressi...
1. Schmid P, Cortes J, Dent R, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: overall survival results from the phase III KEYNOTE-522 study. Presented at: 2024 ESMO Congress; September 13-17, 2024...
In a phase II study presented at the 2017 San Antonio Breast Cancer Symposium, sacituzumab govitecan demonstrated an objective response rate of 34% in patients with heavily pretreated TNBC. In these patients, the median progression-free survival was 5.5 months and the median overall survival was...